²é¿´: 75  |  »Ø¸´: 0

¿ÆÑÐÕ½Éñ¡¤Íõ

Ìú³æ (СÓÐÃûÆø)


[½»Á÷] ÌÇÄò²¡ÔìÄ£µÄ³£¼û¶¯ÎïÄ£ÐÍ£¬ÄãÖªµÀ¼¸¸ö£¿£¿

ʵÑ鶯Îï·¢Õ¹ÖÁ½ñ£¬ÒѾ­ÐγÉÁËÐí¶àÖÖÀàºÍƷϵ£¬Òò´ËÔì¼²²¡Ä£ÐÍʱѡÔñºÏÊʵÄʵÑ鶯Î¾ÍÓÈΪÖØÒª£¬ÏÂÃæ¾ÍΪ´ó¼Ò½éÉÜÊʺÏÌÇÄò²¡µÄ³£¼û¶¯ÎïÄ£ÐÍ¡£



µ¼¶Á£ü

³£¹æT2DM¶¯ÎïÄ£ÐÍ

ת»ùÒòÌÇÄò²¡¶¯ÎïÄ£ÐÍ

ÆäËûDM¶¯ÎïÄ£ÐÍ



01

³£¹æT2DM¶¯ÎïÄ£ÐÍ

#

/ ÊÈɳ·ÊÊó(Psammonys Obesus, PO)

ͼƬ
PO´óÊóÊÇÉú»îÔÚɳĮµØÇøµÄÄö³ÝÀදÎ¸ÃÊó¾ßÓÐÃ÷ÏÔµÄÒȵºËصֿ¹¡£



ÔÚ¸ßÈÈÁ¿ÒûʳÌõ¼þÏÂ(ÊýÌì¡«Á½ÖÜ)£¬90% µÄPO´óÊó¿É×Ô·¢³öÏÖ¸ßÒȵºËØѪ֢£¬²¢°éÓÐÃ÷ÏԵĸßѪÌÇ£¬Ëæºó³öÏÖÒȵºËØˮƽ½µµÍ¡£



PO´óÊóµÄDM·¢²¡´óÖ¿ɷÖΪÒÔÏÂËĸö½×¶Î£º

1£©Æðʼ½×¶Î

¸Ã½×¶ÎÄÚѪÌǼ°ÑªÇåÒȵºËØˮƽ¾ùÕý³£¡£



2£©¸ßÒȵºËØѪ֢ÆÚ

¸ÃÆÚѪÌÇÈÔ±£³ÖÕý³££¬µ«ÑªÇåÒȵºËØÃ÷ÏÔÉý¸ß¡£



3£©¸ßÒȵºËغ͸ßѪÌÇÆÚ

¸ÃÆÚÄÚѪÌÇ>11.1mmol/L¡£



4£©µÍÒȵºËظßѪÌÇÆÚ

¸ÃÆÚÓÉÓÚÒȵº¦Âϸ°û·ÖÃÚ¹¦ÄÜË𺦣¬µ¼ÖµÍÒȵºËغ͸ßѪÌÇ£¬´óÊóÐèÓ¦ÓÃÒȵºËØÖÎÁÆÒÔά³ÖÉú´æ¡£



DuhaultµÈ·¢ÏÖPO´óÊóÔÚIIÐÍDMÍíÆÚ³ÊÒȵºËØÒÀÀµÐÔ£¬ÒÈÏÙ×é֯ѧÏÔʾÓÐÒȵºÑ×´æÔÚ¡£ËµÃ÷Æä¾ßÓгٷ¢IÐÍDM(Latent autoimmune diabetes mellitus in adult,LADA)µÄÌص㣬¹ÊPO´óÊó¿ÉÄÜÊÊÓÃÓÚLADAµÄÑо¿¡£

#

/ ÖйúµØÊó

ͼƬ
×Ô·¢ÐÔDMµØÊóÄ£ÐÍÊǽ«½¡¿µµÄÖйúµØÊóͨ¹ý½üÇ×·±Ö³¶ø»ñµÃ¡£



ÕâÖÖÄ£ÐÍÒÔÇá¡¢ÖжȸßѪÌÇΪÌØÕ÷£¬¶¯ÎïΪ·Ç·ÊÅÖÐÍ£¬ÑªÇåÒȵºËرíÏÖ¶àÑù£¬Òȵº²¡±ä³Ì¶È²»Ò»£¬ÀàËÆÓÚÈËÀàµÄIIÐÍDM¡£



¶àÊýµØÊóDM·¢²¡ÔÚ1ËêÁäÒÔÄÚ£¬ÈºÌå·¢²¡ÂÊԼΪ20.88%¡£

#

/ GK´óÊó(Goto-Kakisaki Wistar Rats)

ͼƬ
GK´óÊóÊÇÒ»¸ö³£ÓõÄ×Ô·¢ÐÔ·Ç·ÊÅÖIIÐÍDMÄ£ÐͶ¯Îï¡£GK´Æ¡¢ÐÛÊó·¢²¡ÂÊÏ൱£¬Ò»°ãÓÚ3¡«4ÖÜÁäʱ·¢ÉúÃ÷ÏÔµÄDM¡£



ÔÚ¸ßѪÌÇ·¢ÉúÇ°£¬³£ÓÐÒ»¶ÎѪÌÇÕý³£Ê±ÆÚ(´Ó³öÉúºóµ½¶ÏÄÌ)£¬Ï൱ÓÚÈËÀàµÄDMÇ°ÆÚ¡£ÆäÌØÕ÷ÓУº

ÆÏÌÑÌǴ̼¤µÄÒȵºËØ·ÖÃÚÊÜË𣬦Âϸ°ûÊýÄ¿¼õÉÙ60%£¬¸ÎÔà¶ÔÒȵºËصÄÃô¸ÐÐÔ½µµÍ£¬µ¼Ö¸ÎÌÇÉú³É¹ý¶à£»¼¡ÈâºÍÖ¬·¾×éÖ¯³ÊÖжÈÒȵºËصֿ¹¡£



GK´óÊóѪѹҲ½ÏÕý³£wistar´óÊó¸ß(µÍÑÎÉãÈëÔ¼¸ß15mmHg,¸ßÑÎÉãÈëÔ¼¸ß24mmHg)¡£



´ËÍ⣬GK´óÊó¾ßÓÐÓëÈËÀàIIÐÍDM΢Ѫ¹Ü²¢·¢Ö¢ÏàËƵĸı䣬ÈçÔ˶¯Éñ¾­´«µ¼ËÙÂʼõÂý¡¢Éñ¾­ÏËάÓнڶÎÐÔÍÑËèÇÊ¡¢ÖáÍ»±äÐÔ¡¢ÊÓÍøĤѪ¹ÜÄÚƤÉú³¤Òò×Ó(VEGF)±í´ïÔö¼Ó¡¢ÊÓÍøĤ¾Ö²¿ÑªÁ÷¼õÉÙ¡¢°×µ°°×Äò¡¢ÉöСÇò»ùµ×ĤÔöºñ¡¢ÉöСÇò·Ê´óºÍÓ²»¯µÈ¡£

#

/ Zucker DM·ÊÅÖ´óÊó(zucker diabetic fatty,ZDF )

ͼƬ
ZDF´óÊóÊdz£ÓõÄIIÐÍDMÄ£ÐͶ¯Îï¡£



¸ÃÊóÓÉÓÚÊÝËØÊÜÌåÍ»±äµ¼Ö¶àʳ¡¢·ÊÅÖͬʱ°éÓиßÒȵºËØѪ֢¡¢¸ß֬Ѫ֢ºÍÖжȸßѪѹ¡£



ÐÛÐÔZDF´óÊóÒ»°ãÓÚ8¡«10ÖܳöÏÖDM£¬ÓÐDMµÄµäÐÍÖ¢×´Èç¶àÒû¡¢¶àÄòºÍÌåÖØÔö¼Ó»ºÂý£¬²¢¿É³öÏÖÉñ¾­²¡±ä¡£ÐÛÐÔZDF´óÊó¼¡ÈâGLUT4±í´ïÃ÷ÏÔ½µµÍ£¬ÆäÒȵº¦Âϸ°ûGLUT2±í´ïÒ²Ã÷ÏÔϵ÷£¬Õâ¿ÉÄÜÊÇZDF´óÊó·¢ÉúIIÐÍÌÇÄò²¡µÄ»úÖÆ¡£



×é֯ѧÑо¿·¢ÏÖ£¬6ÖÜÁä´óÊóÒȵº¼´±íÏÖÓнṹÎÉÂÒºÍÏËά»¯¡¢Òȵº¦Âϸ°ûÍÑ¿ÅÁ£ÏÖÏó£¬Í¬Ê±Òȵº¦Âϸ°ûÊýÁ¿Ô¶µÍÓÚÏàͬÖÜÁäµÄ·ÇDM ZDF´óÊó¡£

#

/ NSYСÊó(Nagoya-Shibata-Yasuda)

NSYСÊóÊÇ´Ójcl ICRÔ¶½»ÏµÐ¡Ê󣬸ù¾ÝÆÏÌÑÌÇÄÍÁ¿Ñ¡Ôñ·±Ö³²úÉúµÄ£¬¾ßÓÐÄêÁäÒÀÀµÐÔ×Ô·¢·¢ÉúDMµÄÌØÕ÷¡£



¸ÃÊóÔÚÈκÎÄêÁ䶼ÎÞÑÏÖصķÊÅÖ£¬Ò²Î޺ܸßˮƽµÄ¸ßÒȵºËØѪ֢£¬µ«ÔÚµÚ24ÖÜÁä³öÏÖÏÔÖøµÄÆÏÌÑÌǴ̼¤µÄÒȵºËØ·ÖÃÚ¹¦ÄܵļõÈõ¡£



²¡ÀíѧÉÏδ¼ûÒȵºÔöÉú»òÑ×ÐԸıäµÈÐÎ̬ѧÒì³££¬ÌáʾNSYСÊó·¢ÉúIIÐÍDMµÄÔ­Òò¿ÉÄÜÊÇÒȵº¦Âϸ°û¶ÔÆÏÌÑÌÇÓÕ·¢µÄÒȵºËØ·ÖÃÚ¹¦Äܸı䡣ÒȵºËصֿ¹¿ÉÄÜÔÚÆä·¢²¡»úÀíÖз¢»ÓÒ»¶¨µÄ×÷Óá£



NSYСÊó½«ÓÐÖúÓÚÈËÃǶÔIIÐÍDMÒÅ´«Ñ§ÇãÏò¼°²¡Àí·¢ÉúµÄ½øÒ»²½Ñо¿¡£

#

/ OLETF´óÊó(Ostuka Long-Evans Tokushima Fatty)

OLETF´óÊóÊǺÓÒ°µÈÀûÓÃLong-Evansϵ´óÊó½¨Á¢µÄ×Ô·¢ÐÔ2ÐÍDMÄ£ÐͶ¯Îï¡£



¸ÃÊóÓÉÓÚµ¨ÄÒÊÕËõËØ(CCK)-AÊÜÌåmRNAµÄ±í´ïÍêȫȱʧ£¬µ¼ÖÂÆäʳÓû¿º½øºÍ·ÊÅÖ£¬Ïû»¯µÀ¶ÔCCK-8´Ì¼¤ÎÞ·´Ó¦£¬ÒÈÏÙµÄÄÚ¡¢Íâ·ÖÃÚ¹¦Äܾù½µµÍ¡£´ËÄ£Ð;ßÓÐIIÐÍDMµÄÌØÕ÷£¬Èç¶àʳ¡¢·ÊÅÖ¡¢¶àÒûºÍ¶àÄò£¬ÄÜ»ºÂýµØ×ÔÈ»²úÉúIIÐÍDM¡£



ѪÇå¸ÊÓÍÈýõ¥ºÍ²ÍºóѪÌÇ

OLETF´óÊó×Ô8ÖÜÁäÆðѪÇå¸ÊÓÍÈýõ¥¡¢µ¨¹Ì´¼ºÍ²ÍºóѪÌǾùÃ÷ÏÔ¸ßÓÚ¶ÔÕÕÊó£¬Ëæ×ÅÄêÁäµÄÔö³¤£¬ÑªÇå¸ÊÓÍÈýõ¥ºÍ²ÍºóѪÌDz»¶ÏÉý¸ß¡£12ÖÜÁäÆ𣬳öÏÖÃ÷ÏÔµÄÒȵºËصֿ¹£»18ÖÜÁäʱ£¬ÒȵºËØÃô¸ÐÐÔԼΪ¶ÔÕÕ×éµÄ20%£»24ÖÜÁäʱ£¬Ñª½¬ÒȵºËØ´ú³¥ÐÔÔö¼Ó£»30ÖÜÁäʱ£¬ÑªTGˮƽ´ïµ½¶ÔÕÕ×éµÄ5±¶£»40ÖÜÁäÒÔºó£¬ÒȵºµÄ·ÖÃÚ¹¦ÄܽµµÍ£»65ÖÜÒÔºó£¬ÑªÌÇÖµ¸ß´ï25mmol/L£¬¶øÃâÒß·´Ó¦ÐÔÒȵºËØ(IRI)ˮƽȴµÍÓÚ40pmol/L¡£



Äòµ°°×

OLETF´óÊóÄòµ°°××Ô30ÖÜÁäÆðÃ÷ÏÔÔö¶à£¬ÇÒËæÄêÁäµÄÔö¼Ó¶øѸËÙÔö¼Ó¡£ÐÛÐÔÊó55ÖÜÁäʱ£¬Äòµ°°×º¬Á¿¿É´ï800mg/dÒÔÉÏ¡£×é֯ѧÑо¿·¢ÏÖ£¬OLETF´óÊóÒÈÏٳʽøÐÐÐÔÏËά»¯¡£



ÒÈÏÙ

20ÖÜÁäʱ£¬ÒÈÏÙ¼´ÓÐÃ÷ÏÔµÄÏËά»¯¡¢ÒȵºÔö´ó£»40ÖÜÁäʱ£¬Òȵº±»½áµÞ×é֯ȡ´ú£»70ÖÜÁäʱ£¬ÒÈÏÙ¼«¶ÈήËõ£¬ÒÈÏÙ×éÖ¯±»Ö¬·¾ºÍ½áµÞ×éÖ¯´úÌæ¡£



ÉöСÇò

´ËÍ⣬OLETF´óÊóÔÚ22ÖÜÁäʱ£¬¼´¿É³öÏÖÉöСÇò»ùµ×ĤÔöºñ£»40ÖÜÁäÒÔºó£¬ÐÛÐÔOLETF´óÊóÉöСÇòÔö´ó£¬ÉöСÇòĤ»ùÖÊÔöÉú¼°ÉöСÇò»ùµ×ĤÔöºñ£»70ÖÜÁäʱ£¬¼¸ºõÔÚÿһ¸öÉöСÇòÖÜΧ¶¼¿É¼û±»À©ÕŵÄëϸѪ¹Ü°üΧµÄPAS-ÑôÐÔ½á½Ú£¬ÕâÖÖ½á½ÚÐԵĸıäÅòÕ͵½ÉöСÇòĤ»ùÖÊ£¬OLETF´óÊóµÄÉöÔà±ä»¯ºÜÀàËÆÈ˵ÄDM½á½ÚÐÔÉöСÇòÓ²»¯Ö¢¡£



ÒÔÉÏÒÈÏÙºÍÉöÔ಻ͬ½×¶ÎµÄ²¡Àí±ä»¯£¬ÓëÁÙ´²IIÐÍDM»¼ÕߵIJ¡Àí±íÏÖ¼«ÎªÏàËÆ£¬ÎªÑо¿IIÐÍDM¼°Æä²¢·¢Ö¢µÄ·¢²¡»úÖƺÍÒȵºËصֿ¹¸ÉÔ¤´ëÊ©µÄÆÀ¼Û£¬ÌṩÁËÁ¼ºÃµÄʵÑ鶯ÎïÄ£ÐÍ¡£

#

/ db/dbСÊó

ͼƬ
db/dbСÊóÌÇÄò²¡·¢²¡ÏµÊÝËØÊÜÌåÍ»±äËùÖ£¬³Ê³£È¾É«ÌåÒþÐÔÒÅ´«¡£



¸ÃÊóÔÚ10¡«14ÈÕÁäʱ¾Í³öÏÖ¶àʳ¡¢¸ßÒȵºËØѪ֢£¬µ«4ÖÜÁäʱѪÌÇÈÔά³ÖÕý³££¬Ëæºó¸ÃÊóÌåÖØÖð½¥Ôö¼Ó£¬³öÏÖ¸ßѪÌÇ¡£



2¡«3ÔÂÁäʱ¾¡¹ÜÒȵºËØˮƽΪÕý³£Ê±µÄ6¡«10±¶£¬µ«ÑªÌÇˮƽ¿É´ï22¡«33mmol/L¡£



Ô¼3¡«6ÔÂÁäʱÒȵºËØˮƽÖð½¥Ï½µÖÁµÍÓÚÕý³£Ë®Æ½,¸ÃÆÚСÊóÌåÖØÃ÷ÏÔϽµ£¬²¢³öÏÖ֢ͪ£¬×é֯ѧÏÔʾÏÔÖøµÄ¦Âϸ°û»µËÀ£¬Èçȱ·¦ÒȵºËØÖÎÁÆ£¬¸ÃСÊó´æ»î²»³¬¹ý10Ô¡£



db/dbСÊóÁíÒ»¸öÌصãΪ£ºÆäѪÇåÒȸßÌÇËصÄˮƽ½ÏÕý³£¶ÔÕÕÉý¸ß2±¶ÒÔÉÏ¡£



db/dbСÊóÊÇÊÊÓÃÓÚÑо¿IIÐÍÌÇÄò²¡·¢²¡»úÖƵĶ¯ÎïÄ£ÐÍ¡£

#

/ob/obСÊó

ͼƬ
ob/obСÊóΪ2ÐÍÌÇÄò²¡Ä£ÐͶ¯ÎÊô³£È¾É«ÌåÒþÐÔÒÅ´«¡£



ob/obСÊóÌÇÄò²¡·¢²¡ÊÇÓÉÓÚob»ùÒòÍ»±ä£¬Ôì³ÉÆä±àÂëµÄµ°°×leptinȱ·¦£¬ÒýÆð¸ÎÖ¬·¾Éú³ÉºÍ¸ÎÌÇÔ­ÒìÉúÏÔÖøÔö¼Ó£¬¸ßѪÌÇÓִ̼¤ÒȵºËØ·ÖÃÚ£¬ÒýÆðÒȵºËصֿ¹£¬´Ì¼¤Ö¬·¾µÄÐγɡ£ob/obСÊóÌåÖØ¿É´ï90¿ËÖ®¶à¡£



ob/obСÊóÖ¢×´µÄÇáÖØÈ¡¾öÓÚÒÅ´«±³¾°¡£´¿ºÏÌ嶯Îï±íÏÖΪ·ÊÅÖ£¬Ã÷ÏԵĸßѪÌǼ°¸ßÒȵºËØѪ֢¡£



ob/ob/6JСÊóÒȵºËØˮƽ¿É´ïÕý³£Ð¡ÊóµÄ10¡«50±¶£¬µ«ÆäѪÌdz£Ö»ÓÐÇá¶ÈµÄÉý¸ß¡£



×é֯ѧÏÔʾob/obСÊóÒȵº¦Âϸ°ûÏÔÖøÔöÉú¡¢·Ê´ó,¶øÒȵºAϸ°û¡¢Dϸ°û¼°PPϸ°ûÊýÁ¿Ã÷ÏÔ¼õÉÙ¡£

#

/ KKÊó

KKСÊóÊÇÒ»ÖÖÇá¶È·ÊÅÖÐÍIIÐÍÌÇÄò²¡¶¯ÎËüÓëC57BL/6JСÊóÔÓ½»£¬²¢½øÐнüÇ×·±Ö³£¬µÃµ½Toronto-KK(T-KK)СÊó¡£



½«»ÆÉ«·ÊÅÖ»ùÒò(¼´Ay)תÖÁKKСÊó£¬KKAyÊó£¬ÓëKKСÊóÏà±È£¬KKAyÊóÓÐÃ÷ÏԵķÊÅÖºÍÌÇÄò²¡Ö¢×´¡£



KKСÊóÓÐÃ÷ÏԵĶàʳ£¬´Ó5ÖÜÁäÆðѪÌÇ¡¢ÑªÒȵºËØˮƽÖð²½Éý¸ß£¬ÖÁ5ÔÂÁäʱÌåÖØ¿É´ï50¿Ë£¬·Ç¿Õ¸¹ÑªÌdz£µÍÓÚ17mmol/L£¬·Ç¿Õ¸¹ÑªÒȵºËØ¿É´ï1200ug/mL£»1ËêÁäʱ¶àʳ¡¢¸ßѪÌÇ¡¢¸ßÒȵºËØѪ֢¡¢·ÊÅÖ¼°¸ÎÔà¶ÔÒȵºËصÄÃô¸ÐÐÔ¿É×Ô·¢»Ö¸´Õý³££¬µ«ÌÇÄò²¡KKСÊóÉúÃü³£Ã÷ÏÔËõ¶Ì¡£



´ËÍ⣬KKСÊó¿Õ¸¹ÒȸßÌÇËØˮƽÉý¸ß£¬ÇÒ²»ÊÜÆÏÌÑÌÇÒÖÖÆ¡£



×é֯ѧÏÔʾ¦Âϸ°ûÓÐÍÑ¿ÅÁ£ºÍÌÇÔ­½þÈó£¬Ëæºó³öÏÖÒȵº·Ê´óºÍ¸ÎÖ¬·¾»¯ºÍÖ¬·¾×éÖ¯Ôö¶à¡£



02

ת»ùÒòÌÇÄò²¡¶¯ÎïÄ£ÐÍ

ת»ùÒò¶¯Îï(transgenic animal)¼¼ÊõÊÇͨ¹ýÒÅ´«¹¤³ÌµÄÊֶζԶ¯Îï»ùÒò×éµÄ½á¹¹»ò×é³É½øÐÐÈËΪµÄÐÞÊλò¸ÄÔ죬²¢Í¨¹ýÏàÓ¦µÄ¶¯ÎïÓýÖÖ¼¼ÊõʹµÃÕâЩ¾­ÐÞÊθÄÔìºóµÄ»ùÒò×éÔÚÊÀ´ú¼äµÃÒÔ´«µÝºÍ±íÏÖ¡£



ÀûÓÃÕâÒ»¼¼Êõ£¬ÈËÃÇ¿ÉÒÔÔÚ¶¯Îï»ùÒò×éµÄÌض¨Î»µãÒýÈëËùÉè¼ÆµÄ»ùÒòÍ»±ä£¬Ä£ÄâÔì³ÉÈËÀàÒÅ´«ÐÔ¼²²¡µÄ»ùÒò½á¹¹»òÊýÁ¿Òì³£¡£



¿ÉÒÔͨ¹ý¶Ô»ùÒò½á¹¹½øÐÐÐÞÊΣ¬ÔÚ¶¯Îï·¢Éú¡¢·¢ÓýµÄÈ«¹ý³ÌÖÐÑо¿ÌåÄÚ»ùÒòµÄ¹¦Äܼ°Æä½á¹¹¹¦ÄܵĹØϵ¡£



ÓйØIÐÍ¡¢IIÐÍDMºÍÇàÉÙÄê·¢²¡µÄ³ÉÈËÐÍÌÇÄò²¡(maturity-onset diabetes of youth,MODY)µÄת»ùÒòDM¶¯Îï¾ùÓб¨µÀ¡£

#

/ MKRСÊó¶¯ÎïÄ£ÐÍ

MKRСÊóÊÇÓÉFern¨¢ndezµÈÅàÓý³öµÄIIÐÍDMת»ùÒò¶¯ÎïÄ£ÐÍ¡£



¸ÃСÊó¹Ç÷À¼¡¹ý¶È±í´ïʧ»îµÄIGF-1ÊÜÌ壬ʧ»îµÄIGF-1ÊÜÌåÓëÄÚÔ´ÐÔIGF-1ÊÜÌå¼°ÒȵºËØÊÜÌåÐγÉÔÓºÏÊÜÌ壬¸ÉÈÅÕâЩÊÜÌåµÄÕý³£¹¦ÄÜ£¬µ¼ÖÂÃ÷ÏÔÒȵºËصֿ¹¡£



¸ÃСÊó2ÖÜÁä¼´ÓÐÃ÷ÏԵĵĸßÒȵºËØѪ֢£¬5ÖÜÁäºó¿Õ¸¹¼°½øʳºóѪÌÇÖð½¥Éý¸ß£¬7¡«12ÖÜÁä¼´ÓÐÃ÷ÏÔÌÇÄÍÁ¿Òì³£¡£PPAR- ¼¤¶¯¼Á WY14¡¢643ÖÎÁƿɾÀÕýMKRСÊóÌÇ´úлÒì³£¡£

#

/  MODY2¶¯ÎïÄ£ÐÍ

zhangµÈÀûÓûùÒòÇóý¼¼ÊõÖƵøÎÔàÆÏÌÑÌǼ¤Ã¸(GCK) -СÊ󣬷¢ÏÖËæ×Åʱ¼äÑÓ³¤£¬¸ÃÊóѪÌÇÖð½¥Éý¸ß£¬ÌÇÄÍÁ¿¼õÍË£¬6ÖÜÁäСÊó¿Õ¸¹ÑªÌÇÏÔÖø¸ßÓÚ¶ÔÕÕ×éСÊó£¬ÕâÖÖ¸Îϸ°ûGCK»îÐÔ¼õÍËËùÒýÆðµÄ¼²²¡ÓëÈËMODYÏàËÆ£¬¿É×÷ΪMODYµÄ¶¯ÎïÄ£ÐÍ¡£

#

/ ÏßÁ£ÌåÌÇÄò²¡

SilvaµÈ·¢ÏÖ¦Âϸ°ûTfam(mitochondrial transcriptionfactor A)Í»±äµÄСÊ󣬴óÔ¼5ÖÜÁäʱ·¢ÉúÌÇÄò²¡£¬±íÏÖΪÑÏÖØmtDNAºÄ½ß£¬Ñõ»¯Á×Ëữ²»×ãºÍ7~9ÖÜʱÒȵºÄڿɹ۲쵽Òì³£µÄÏßÁ£Ì壬³ÊÏÖÏßÁ£ÌåÌÇÄò²¡µÄ¸Ä±ä¡£

#

/ GDM(ÈÑÉïÌÇÄò²¡)Ä£ÐÍ

ÈÑÉïÆÚÒȵºËصֿ¹¿ÉÒýÆðÈÑÉïÌÇÄò²¡£¬»¼ÕßÌ¥¶ùµäÐÍÌØÕ÷ÊǾ޴ó¶ù£¬³ÉÄêºó»¼·ÊÅÖºÍ2ÐÍÌÇÄòµÄ¸ÅÂÊÉÏÉý¡£



Yama***aµÈ·¢ÏÖÔÓºÏÌåC57BL/PKsJ-db/+СÊó·¢ÉúGDM¡£ÈÑÉïÒýÆðPI3KÓëIRS-1½âÀ룬ÓëIR½áºÏ»îÐÔÔö¼Ó,ÒȵºËؽ鵼µÄ¾«°±ËáÁ×ËữÔö¶à£¬¶øIRS-1±í´ï¼°ÆäÀÒ°±ËáÁ×Ëữ¼õÉÙ´Ó¶øʹIRS-1½áºÏ¼°¼¤»îPI3KÄÜÁ¦Ï½µ£¬ÒȵºËع¦Äܲ»ÄÜ·¢»Ó£¬³öÏÖÒȵºËصֿ¹¡£

#

/NOD-RIP-B7-1(Nonobese Diabetic-Rat

Insulin Promoter-B7-1)

ΪÁËÑо¿BÁÜ°Íϸ°ûÔÚIÐÍDM·¢²¡ÖеÄ×÷Óã¬WongµÈÀûÓÃת»ùÒò¼¼ÊõÖƵÃÁËNOD-RIP-B7-1(Nonobese Diabetic-Rat Insulin Promoter-B7-1)ת»ùÒòСÊó¡£



¸ÃСÊóÓÉÓÚ¹ý¶È±í´ï¸¨Öú´Ì¼¤Òò×ÓB7.1¶øÖÂDM·¢²¡Ê±¼ä½ÏÕý³£NODСÊóÃ÷ÏÔÌáÇ°£¬ÔÚ12ÖÜÁä¼´·¢ÉúDM¡£



Ëæ×ŶÔDMÑо¿µÄÖð²½ÉîÈ룬ÏàÓ¦µÄDM¶¯ÎïÄ£ÐÍ·¢Õ¹ÊÆÔÚ±ØÈ»£¬×ª»ùÒò¶¯ÎïµÄ½¨Á¢½«ÎªDMÑо¿Ìṩ¸ü¿ÆѧÓÐЧµÄ¹¤¾ß¡£



03

ÆäËûDM¶¯ÎïÄ£ÐÍ

#

/  ¼¤ËØÐÔDM¶¯ÎïÄ£ÐÍ

¼¤ËØÐÔDM¶¯ÎïÄ£ÐÍ£º×¢Éä´¹ÌåÇ°Ò¶ÌáÈ¡Îï¡¢Éú³¤ËØ¡¢ÉöÉÏÏÙƤÖʼ¤ËØ¡¢¼××´ÏÙËØ»òÒȸßѪÌÇËØ£¬¾ù¿ÉÖ±½Ó»ò¼ä½Ó²úÉúDM¡£

#

/ ²¡¶¾ÐÔDM¶¯ÎïÄ£ÐÍ

ÀûÓÃÄÔ-Ðļ¡Ñײ¡¶¾(EMC-M²¡¶¾)ºÍ¿ÂÈø»ù²¡¶¾µÈ£¬Ê¹Ä³Ð©ÖÖÊôµÄСÊóÒȵº¦Âϸ°ûÍÑ¿ÅÁ£¡¢»µËÀ,µ¼ÖÂÒȵº¦Âϸ°ûÆÆ»µ£¬²úÉúÀàËƵÄ1ÐÍDM¡£

#

/ ÃâÒßÐÔDM¶¯ÎïÄ£ÐÍ

¾²Âö×¢É俹ÒȵºËØ¿¹Ì壬»òÓÃͬÖÖ»òÒìÖÖÒȵºËصĸ¥ÊÏ×ô¼Á¸´ºÏÎï¼°¿¹ÑªÇåÃâÒߣ»»òÓÃͬÖÖ»òÒìÖÖÒÈÏÙ+¸¥ÊÏ×ô¼Á£¬ÃâÒ߶¯Îï¾ù¿ÉÔÚÊýСʱºó²úÉúÒ»¹ýÐÔ¸ßѪÌÇ¡£



Æä»úÖÆÊÇÄÚÔ´ÐÔÒȵºËØÓëÊäÈëµÄ¿¹Ìå½áºÏµ¼ÖÂÄÚÔ´ÐÔÒȵºËؽµµÍ¶øÖÂDM¡£

#

/ ÏÂÇðÄÔÐÔDM¶¯ÎïÄ£ÐÍ

ÓõçÄý·¨»ò×¢ÉäÁò´úÆÏÌÑÌǽð£¬ËðÉËÇðÄÔϲ¿¸¹ÄÚ²àºË(VMH)±¥ÖÐÊ࣬¿Éʹ³ÉÊ춯Îï²úÉú¹ý¶ÈÉãʳ¡¢·ÊÅÖ£¬Ö±ÖÁ²úÉúDM¡£
»Ø¸´´ËÂ¥
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
Ïà¹Ø°æ¿éÌøת ÎÒÒª¶©ÔÄÂ¥Ö÷ ¿ÆÑÐÕ½Éñ¡¤Íõ µÄÖ÷Ìâ¸üÐÂ
×î¾ßÈËÆøÈÈÌûÍƼö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[˶²©¼ÒÔ°] ¶×Ò»¸öÄÐÅóÓÑ +23 ÒÁÒÁɯ±´À­ 2024-05-17 33/1650 2024-05-20 15:48 by δÀ´¿ÉÆÚ¼òÖ±²»¶
[½Ìʦ֮¼Ò] ²©Ê¿È¥¸ßУ¾ÍÊÇΪÁËÓк®Êî¼ÙÂ𣿠+17 wenwen0825 2024-05-16 23/1150 2024-05-20 11:59 by zyqchem
[¿¼²©] ±¾¿Æ³öÉí²»ºÃÊDz»Êǻᱻֱ½Óˢѽ +3 δÀ´¸»ÆÅÍÜ 2024-05-20 3/150 2024-05-20 10:38 by °²ËþÍßÀ­¶à
[»ù½ðÉêÇë] ÓÐÖªµÀ¹¤²Äe01Çé¿öµÄÂ𣿠+13 xiaopang8958 2024-05-17 19/950 2024-05-20 09:52 by Íɱä123~
[ÕÒ¹¤×÷] ÉÜÐËÎÄÀíѧԺÔõôÑù£¿ÓÐûÓпӰ¡ +7 zhaojiang427 2024-05-16 16/800 2024-05-20 08:29 by zhaojiang427
[˶²©¼ÒÔ°] º£Íⲩʿ£¬¹úÄÚ²©ºóÕÒ¹¤×÷Çó½¨Òé +8 905452934 2024-05-16 19/950 2024-05-19 17:56 by ËýÔÚѧϰ
[ÂÛÎÄͶ¸å] Nano-Micro LettersͶ¸å¿ÉÒÔÓÃPDFÉÏ´«Âð 5+4 962511369 2024-05-18 4/200 2024-05-19 15:47 by ca0yan9
[ÂÛÎÄͶ¸å] ÍƼöתͶ£¨ transfer pending£©ÊÇ·ñÓÐÓã¿ 50+3 lily5289 2024-05-17 7/350 2024-05-19 15:11 by wanghuawei
[ÂÛÎÄͶ¸å] ÇóÍƼöÆÚ¿¯ 20+3 ºÃÀ§ºÃÀ§a 2024-05-18 4/200 2024-05-19 11:30 by nono2009
[˶²©¼ÒÔ°] ÓÖÈ̲»×¡ÏëͲÛÎĿƵÄѧÊõȦ +6 nvizqxuf 2024-05-18 8/400 2024-05-19 10:04 by nvizqxuf
[ÂÛÎÄͶ¸å] ÇóÆÚ¿¯ÍƼö 30+3 jxhx666666 2024-05-15 6/300 2024-05-19 07:31 by ÆÚ¿¯·¢±í רÖø³ö
[¿¼²©] Ïë±»211ÒÔÉϸßУ¿ÎÌâ×é½ÓÊÕ +8 ·çÆð²×À½ 2024-05-16 10/500 2024-05-19 06:52 by Guo369
[»ù½ðÉêÇë] ºÓ±±Ê¡»ù½ð +11 3101251516 2024-05-16 18/900 2024-05-18 11:41 by ÏþÏþ°®´ä´ä
[ÁôѧDIY] ÇóÖú£ºÒ½ÉúÏëÈó +7 safrina 2024-05-15 7/350 2024-05-17 18:50 by ¿¨Æ¤°ÉÀ²123
[ÂÛÎÄͶ¸å] µ±Ç°scientific reports»¹ÖµµÃͶ¸åô£¿ +5 lizhengke06 2024-05-14 6/300 2024-05-17 18:28 by dxcharlary
[ÂÛÎÄͶ¸å] Ͷ¸å³É¹¦ºóÓÖÏë³·»Ø +5 otani 2024-05-16 5/250 2024-05-17 16:02 by topedit
[˶²©¼ÒÔ°] ÁìÑøСº¢ +15 Yyds55 2024-05-14 15/750 2024-05-17 09:53 by ÌïÔ°1983
[ÂÛÎÄͶ¸å] ÊÖ¸åÌá½»ÁËÁ½±é 10+3 Ñõ»¯»¹Ô­¼Á 2024-05-14 4/200 2024-05-16 22:43 by nono2009
[½Ìʦ֮¼Ò] Ëο­ +10 yexuqing 2024-05-14 10/500 2024-05-16 09:21 by shl2112501
[Óлú½»Á÷] ÎÞË®ÁòËáÄƳýË® 50+4 ÌÒÌÒPXS 2024-05-13 4/200 2024-05-14 17:46 by СÈâ¸É
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û